ERBB2 and neoplasm: However, when combined with the vaccinia virus encoding HER2/neu and administered to the tumor microenvironment, mice develop systemic anti-neu immunity, display significantly reduced tumor volume and systemic MDSCs infiltration, and exhibit a significant anti-tumor response.